Trials / Completed
CompletedNCT02054702
Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
Protocol 331-13-008: An Exploratory, Multicenter, Open-label, Flexible-dose Brexpiprazole (OPC-34712) Trial in Adults With Acute Schizophrenia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 97 (actual)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore changes in efficacy, cognitive functioning, and safety of flexibly-dosed Brexpiprazole monotherapy in subjects with acute schizophrenia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brexpiprazole | Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally |
| DRUG | Aripiprazole | Up to 20 mg/day, once daily dose, tablets, orally |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2014-06-01
- Completion
- 2014-07-01
- First posted
- 2014-02-04
- Last updated
- 2015-12-30
- Results posted
- 2015-12-01
Source: ClinicalTrials.gov record NCT02054702. Inclusion in this directory is not an endorsement.